Traditional drug delivery systems for AMD, particularly in the case of wet AMD, often require frequent and invasive injections of anti-VEGF drugs, which can be burdensome for patients and limit therapeutic efficacy. The gene discussed is VEGFA; the disease is wet macular degeneration.